Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Operating Margin (2016 - 2025)

Historic Operating Margin for Seres Therapeutics (MCRB) over the last 9 years, with Q3 2025 value amounting to 6403.7%.

  • Seres Therapeutics' Operating Margin changed N/A to 6403.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 29466.95%, marking a year-over-year increase of 1728814900.0%. This contributed to the annual value of 154.44% for FY2023, which is 23696100.0% up from last year.
  • Per Seres Therapeutics' latest filing, its Operating Margin stood at 6403.7% for Q3 2025.
  • Seres Therapeutics' 5-year Operating Margin high stood at 53.98% for Q3 2021, and its period low was 57850.0% during Q4 2023.
  • Moreover, its 4-year median value for Operating Margin was 1716.23% (2022), whereas its average is 8085.74%.
  • The largest annual percentage gain for Seres Therapeutics' Operating Margin in the last 5 years was 52468100bps (2023), contrasted with its biggest fall of -576724600bps (2023).
  • Quarter analysis of 4 years shows Seres Therapeutics' Operating Margin stood at 684.56% in 2021, then soared by 74bps to 177.54% in 2022, then plummeted by -32484bps to 57850.0% in 2023, then surged by 89bps to 6403.7% in 2025.
  • Its last three reported values are 6403.7% in Q3 2025, 57850.0% for Q4 2023, and 14382.58% during Q3 2023.